Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS study

Abstract

This study shows that the Canadian TOR may be an important tool for early treatment optimization.

Predicting the severity of relapsing-remitting MS: The contribution of cross-sectional and short-term follow-up MRI data

“…by the absence of accumulating morphological damage or clinical disease progression. 21,22 However, it also needs to be highlighted that the EDSS at baseline was already a very good predictor of conversion to SPMS in our cohort, better than any morphological variable. This is not surprising considering that the clinical assessment provides a comprehensive view on patients' disease severity, especially when disease duration is incorporated, as within the MSSS.…”

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon‐β therapy

“…Fingolimod and natalizumab are also approved for patients with rapidly evolving severe RRMS, defined as two or more disabling relapses in 1 year and with one or more Gd-enhancing lesions on brain MRI or a significant increase in T2 lesion load compared with a previous recent MRI scan [17,18]. In addition to the EU health authority definitions of 'non-response', various treatment optimization guidelines have described suboptimal response based on the presence of combinations of relapse, disease progression [as measured by the Expanded Disability Status Scale (EDSS)] and MRI criteria [16,[26][27][28][29][30]. The presence of at least two of three clinical or MRI variables (at least one relapse, confirmed increase of at least one point on the EDSS, and more than two Gd-enhancing or new/newly enlarged T2 lesions) during the first 12 months of therapy has been shown in a study of RRMS patients treated with IFNb to be predictive of [32].…”

Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases

“…[19][20][21] No efficacy was defined as no change in relapse rate, or having relapses more than twice within 2 years, or disability progression. We included only patients who had received IFN-β for at least 2 years, in our analysis for primary and secondary outcomes.…”